1. Suppression of integrin α3β1 in breast cancer cells reduces COX-2 gene expression and inhibits tumorigenesis, invasion, and crosstalk to endothelial cells
- Author
-
Kimberly B. Svenson, Fedor Berditchevski, Xianhui Wang, Kara Mitchell, Rafal Sadej, Katerina Gkirtzimanaki, Aristides G. Eliopoulos, C. Michael DiPersio, Whitney M. Longmate, and Jihe Zhao
- Subjects
Cancer Research ,Cell ,Mice, Nude ,Breast Neoplasms ,Cell Communication ,Biology ,medicine.disease_cause ,Article ,Gene Expression Regulation, Enzymologic ,Metastasis ,Mice ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,RNA, Messenger ,RNA, Small Interfering ,Cell adhesion ,Integrin alpha3beta1 ,Cancer ,Endothelial Cells ,medicine.disease ,Xenograft Model Antitumor Assays ,Endothelial stem cell ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Oncology ,Cyclooxygenase 2 ,Immunology ,Cancer research ,Female ,Breast disease ,Carcinogenesis - Abstract
Integrin receptors for cell adhesion to extracellular matrix have important roles in promoting tumor growth and progression. Integrin α3β1 is highly expressed in breast cancer cells in which it is thought to promote invasion and metastasis; however, its roles in regulating malignant tumor cell behavior remain unclear. In the current study, we used short-hairpin RNA (shRNA) to show that suppression of α3β1 in a human breast cancer cell line, MDA-MB-231, leads to decreased tumorigenicity, reduced invasiveness, and decreased production of factors that stimulate endothelial cell migration. Real-time PCR revealed that suppression of α3β1 caused a dramatic reduction in expression of the cyclooxygenase-2 (COX-2) gene, which is frequently overexpressed in breast cancers and has been exploited as a therapeutic target. Decreased COX-2 was accompanied by reduced prostaglandin E2 (PGE2), a major prostanoid produced downstream of COX-2 and an important effector of COX-2 signaling. shRNA-mediated suppression of COX-2 showed that it has a role in tumor cell invasion and cross-talk to endothelial cells. Furthermore, treatment with PGE2 restored these functions in α3β1-deficient MDA-MB-231 cells. These findings identify a role for α3β1 in regulating two properties of tumor cells that facilitate cancer progression: invasiveness and ability to stimulate endothelial cells. They also reveal a novel role for COX-2 as a downstream effector of α3β1 in tumor cells, thereby identifying α3β1 as a potential therapeutic target to inhibit breast cancer. Cancer Res; 70(15); 6359–67. ©2010 AACR.
- Published
- 2010